Megalis is a tadalafil tablet brand associated with Macleods Pharmaceuticals. Current Indian market records document Megalis in 5 mg, 10 mg and 20 mg strengths, while active regulatory records outside India independently identify Macleods Pharmaceuticals Ltd. in India as the manufacturer of documented Megalis 10 mg and 20 mg tablets.
The evidence therefore supports a more precise product picture than simply calling every Megalis listing a Macleods-manufactured tablet. Macleods is directly documented as manufacturer for specific 10 mg and 20 mg regulatory records, while current Indian listings identify the company as marketer across the 5 mg, 10 mg and 20 mg products.
This page focuses on Megalis as a specific product entity. Broader company analysis belongs on Macleods tadalafil, the wider market map belongs on Indian tadalafil brands, and regulatory questions about approved generic tadalafil belong on the generic tadalafil guide.
Current Indian pharmacy records document Megalis 5 mg, 10 mg and 20 mg as tadalafil tablet products associated with Macleods Pharmaceuticals. The 5 mg presentation is currently listed in a ten-tablet strip, while the 10 mg and 20 mg presentations are currently shown in four-tablet packs.
For the 10 mg and 20 mg products, separate active regulatory records provide stronger manufacturer evidence: both list tadalafil tablets under the Megalis name and explicitly identify Macleods Pharmaceuticals Ltd. in India as manufacturer.
| Product fact | Documented Megalis context |
|---|---|
| Brand | Megalis |
| Active ingredient | Tadalafil |
| Documented strengths | 5 mg, 10 mg, 20 mg |
| Dosage form | Tablet |
| Current Indian company association | Macleods Pharmaceuticals Pvt Ltd listed as marketer |
| Direct manufacturer evidence | Macleods Pharmaceuticals Ltd. for documented Megalis 10 mg and 20 mg regulatory records |
| Manufacturer country in those regulatory records | India |
Current Indian market records support a pure-tadalafil Megalis strength range of 5 mg, 10 mg and 20 mg. Each strength identifies the amount of tadalafil in the tablet rather than a separate active drug.
The evidence is not identical for every strength. Megalis 10 mg and 20 mg have both current Indian market documentation and regulatory records explicitly naming Macleods as manufacturer, while the 5 mg presentation is well documented in the current Indian market but is not assigned the same manufacturer claim on this page without equivalent product-specific regulatory evidence.
This source distinction allows the strength range to be described without overstating what is known about every individual presentation.
| Megalis strength | Current Indian market evidence | Direct manufacturer evidence used here |
|---|---|---|
| 5 mg | Documented as tadalafil product associated with Macleods | Not asserted beyond current market company association |
| 10 mg | Documented as tadalafil 10 mg | Macleods explicitly named as manufacturer in regulatory record |
| 20 mg | Documented as tadalafil 20 mg | Macleods explicitly named as manufacturer in regulatory record |
Megalis identifies the commercial product brand, tadalafil identifies the active pharmaceutical ingredient and Macleods Pharmaceuticals identifies the company connected to the product. These terms should not be used interchangeably.
Tadalafil appears under many brands from different companies, and Macleods has a broader pharmaceutical portfolio than Megalis alone. Megalis therefore represents one specific product-family relationship within the wider tadalafil market.
Company-level context belongs on the Macleods tadalafil page rather than being expanded into a corporate profile here.
| Entity | Meaning |
|---|---|
| Tadalafil | Active pharmaceutical ingredient |
| Megalis | Commercial tadalafil brand |
| Macleods Pharmaceuticals | Company associated with the documented Megalis products |
| Megalis 5 / 10 / 20 | Strength-specific tadalafil tablet presentations |
Current Indian pharmacy records identify Macleods Pharmaceuticals Pvt Ltd as marketer of Megalis products. A marketer relationship establishes the company connected to the current commercial presentation but should not automatically be converted into a physical-manufacturer claim.
For Megalis 10 mg and 20 mg, that additional evidence does exist. Active NAFDAC product records explicitly list Macleods Pharmaceuticals Ltd. as manufacturer, identify India as the manufacturer country and specify tadalafil 10 mg and 20 mg respectively.
The most accurate wording is therefore product-specific: Macleods is the documented marketer in current Indian listings and is directly documented as manufacturer for the 10 mg and 20 mg regulatory products.
| Evidence type | Role established |
|---|---|
| Current Indian Megalis listings | Macleods marketer association |
| Megalis 10 mg regulatory record | Macleods explicitly identified as manufacturer |
| Megalis 20 mg regulatory record | Macleods explicitly identified as manufacturer |
| Megalis 5 mg current listing | Company association established; stronger manufacturer wording not inferred here |
Nigeria's current NAFDAC Greenbook contains active prescription-product records for Megalis 10 Tablets and Megalis 20 Tablets. Both records identify tadalafil as the active ingredient, tablet as the dosage form and Macleods Pharmaceuticals Ltd. as the manufacturer in India.
The records list separate registration numbers for the two strengths and show an approval date of December 2, 2021. Their current active status provides strong independent evidence for the Megalis-Macleods manufacturing relationship for these exact regulatory products.
These are Nigerian regulatory records and should be used for what they prove: product composition, regulatory status in that jurisdiction and manufacturer attribution. They do not by themselves establish approval of Megalis in the United States or another country.
| Regulatory product | Composition | Manufacturer | Record status |
|---|---|---|---|
| Megalis 10 Tablets | Tadalafil 10 mg | Macleods Pharmaceuticals Ltd., India | Active |
| Megalis 20 Tablets | Tadalafil 20 mg | Macleods Pharmaceuticals Ltd., India | Active |
Current Indian market records show different pack formats within the Megalis family. The 5 mg presentation is currently shown as a strip of ten tablets, while current 10 mg and 20 mg listings show four-tablet presentations.
Pack size is useful for identifying a current commercial presentation but should not be treated as a permanent pharmaceutical characteristic. Packaging can change by strength, market, distribution channel or over time.
The more stable product identifiers are the Megalis name, tadalafil ingredient, tablet strength and documented company relationship.
| Current presentation | Documented Indian pack example |
|---|---|
| Megalis 5 mg | Strip of 10 tablets |
| Megalis 10 mg | 4 tablets |
| Megalis 20 mg | 4 tablets |
Megalis can be described in Indian market terms as a branded tadalafil or branded-generic tadalafil product. The established active ingredient tadalafil is sold under the Megalis commercial name and in several documented strengths.
That market terminology is different from a jurisdiction-specific therapeutic-equivalence determination. In the United States, an approved generic product must exist within the FDA approval framework, and therapeutic-equivalence evaluations apply to specific approved products rather than to every foreign brand sharing tadalafil and a matching milligram strength.
The regulatory meaning of generic tadalafil is covered on the generic tadalafil page.
| Statement | Supported interpretation |
|---|---|
| Megalis contains tadalafil | Yes |
| Megalis is a branded tadalafil product | Yes |
| Several Megalis strengths are documented | Yes |
| Same ingredient and strength automatically prove FDA approval | No |
| Same ingredient and strength automatically prove therapeutic equivalence to Cialis | No |
Megalis and Cialis can share tadalafil as their active ingredient and can overlap at nominal strengths such as 5 mg, 10 mg and 20 mg. Those similarities are relevant at the ingredient-and-strength level but do not make the commercial products identical.
Brand identity, company, regulatory application, labeling and bioequivalence evidence remain separate characteristics. A Megalis 20 mg tablet therefore should not be called Cialis simply because both products state tadalafil 20 mg.
The broader branded-versus-generic framework belongs on tadalafil vs Cialis, rather than turning this page into a general comparison.
| Product question | Megalis context |
|---|---|
| Contains tadalafil? | Yes |
| Has strengths that overlap with Cialis? | Yes |
| Same brand as Cialis? | No |
| Automatically the same finished product? | No |
| FDA therapeutic equivalence established by matching strength alone? | No |
Megalis illustrates why regulatory claims need to be attached to a country and exact product. Current Indian market records establish present product availability and Macleods marketer association, while NAFDAC provides direct Nigerian regulatory records for Megalis 10 mg and 20 mg.
Neither type of evidence should be silently converted into U.S. FDA approval. A product can be registered in one jurisdiction and absent, differently branded or covered by another application in another.
For this reason, the page describes Megalis as a documented tadalafil brand while keeping FDA-approved generic status separate unless supported for the exact finished product.
| Evidence | What it establishes | What it does not establish |
|---|---|---|
| Current Indian market listing | Market presentation and Macleods association | FDA approval |
| NAFDAC Megalis 10 record | Nigerian registration plus Macleods manufacturer attribution | Approval in every jurisdiction |
| NAFDAC Megalis 20 record | Nigerian registration plus Macleods manufacturer attribution | U.S. therapeutic equivalence |
| Matching tadalafil strength | Same nominal amount of active ingredient | Automatic bioequivalence |
Megalis 5 mg, 10 mg and 20 mg identify the amount of tadalafil in the documented tablets. Their existence does not mean treatment necessarily progresses through those strengths or that one amount is appropriate for every person or indication.
Tadalafil dosing depends on indication, regimen framework, concomitant medicines, organ function and product-specific instructions. A product strength is therefore distinct from individualized dose selection.
General clinical dosing belongs on the tadalafil dosage guide.
| Product fact | What it does not mean |
|---|---|
| Megalis 5 mg exists | Every user should start at 5 mg |
| Megalis 10 mg exists | 10 mg is appropriate in every context |
| Megalis 20 mg exists | 20 mg is universally preferable |
| Three strengths are documented | They form a mandatory dose-escalation sequence |
Current Indian pharmacy records describe Megalis in several familiar tadalafil treatment contexts. Those retailer summaries can help characterize current market presentation, but they are not a substitute for one universal Megalis prescribing label applicable across countries.
The strongest product claims on this page therefore center on what can be established directly: tadalafil composition, 5 mg, 10 mg and 20 mg strengths, tablet dosage form and Macleods company relationship. Exact approved indications should be interpreted from the authorized labeling applicable to the particular product and jurisdiction.
This prevents general tadalafil information from being presented as though every Megalis pack carries identical regulatory labeling.
| Claim type | Approach used here |
|---|---|
| Megalis brand identity | Directly documented |
| Tadalafil composition | Directly documented |
| 5 mg, 10 mg and 20 mg presentations | Current product records support them |
| Manufacturer of 10 mg and 20 mg regulatory products | Directly documented |
| Universal approved indication wording across markets | Not inferred |
Because Megalis contains tadalafil, its active pharmacologic component belongs to the phosphodiesterase type 5 inhibitor class. PDE5 inhibition reduces degradation of cyclic GMP in tissues where nitric oxide-cGMP signaling is active.
That mechanism comes from tadalafil rather than from the Megalis brand name. Different tablet strengths do not create different basic pharmacologic targets.
The molecular pathway is covered in depth on how tadalafil works.
| Mechanism feature | Megalis context |
|---|---|
| Active drug | Tadalafil |
| Drug class | PDE5 inhibitor |
| Key signaling pathway | Nitric oxide / cGMP |
| Does strength change the basic drug target? | No |
| Does the Megalis brand create a different mechanism? | No |
Because Megalis contains tadalafil, clinically important tadalafil contraindication and interaction principles remain relevant. Major considerations include potentially dangerous blood-pressure interactions with nitrates and guanylate cyclase stimulators, together with other drug and patient-specific factors.
The active-ingredient safety framework should still be distinguished from exact Megalis labeling. A CIALIS label or another tadalafil product's prescribing information should not simply be presented as though it were the authorized Megalis label in every jurisdiction.
Detailed tadalafil safety belongs on tadalafil contraindications, tadalafil drug interactions and tadalafil side effects.
| Safety layer | Appropriate interpretation |
|---|---|
| Tadalafil contraindications | Relevant active-ingredient context |
| Tadalafil interactions | Relevant active-ingredient context |
| Exact Megalis instructions | Require product- and jurisdiction-specific information |
| Another tadalafil brand's label | Should not automatically be treated as Megalis labeling |
Macleods Pharmaceuticals has a much broader medicine portfolio than Megalis alone, and the company's relationship with tadalafil can be examined at a different entity level from the individual brand. This page uses company information only where it helps establish Megalis identity, marketed strengths and documented manufacturer status.
The company-wide tadalafil context belongs on the Macleods tadalafil page, while comparisons across Indian brands belong on the Indian tadalafil brands hub.
Keeping that boundary prevents Megalis from becoming a duplicate manufacturer profile.
| Question | Best page |
|---|---|
| What is Megalis? | This page |
| Which Megalis strengths are documented? | This page |
| What evidence links Macleods to Megalis manufacturing? | This page at product level |
| What is Macleods' broader tadalafil context? | Macleods tadalafil |
| Which other Indian tadalafil brands exist? | Indian tadalafil brands |
Megalis product claims are strongest when composition, strength and company role can be traced to a product-specific source. Current Indian pharmacy records provide useful market evidence for 5 mg, 10 mg and 20 mg, while NAFDAC regulatory records directly establish the manufacturer relationship for the 10 mg and 20 mg products registered there.
Different sources answer different questions. A pharmacy listing is useful for current marketed presentation and marketer information, while a regulator explicitly naming the manufacturer provides stronger evidence for manufacturing attribution.
FDA approval or U.S. therapeutic-equivalence claims require U.S.-specific evidence and should not be inferred from Indian market listings or foreign regulatory registration.
| Source type | Best-supported conclusion |
|---|---|
| Current Indian pharmacy record | Strength, current pack and marketer association |
| NAFDAC product record | Composition, regulatory status and explicit manufacturer for that registered product |
| FDA Orange Book | U.S.-specific approved-product and therapeutic-equivalence context |
| Anonymous export storefront | Insufficient alone for strong manufacturer or regulatory claims |
Megalis is sometimes treated as though the brand name, active ingredient and company name all mean the same thing. In reality, Megalis is the product brand, tadalafil is the drug molecule and Macleods is the company associated with the documented products.
Another mistake is to apply the strongest manufacturer evidence to every strength without checking the source. Current regulatory records directly name Macleods as manufacturer for Megalis 10 mg and 20 mg, while the 5 mg claim on this page remains at the current Indian market-association level.
Finally, shared tadalafil content and matching nominal strengths do not by themselves establish that Megalis is the same finished product as Cialis or an FDA-approved therapeutic equivalent.
| Misunderstanding | Correct interpretation |
|---|---|
| Megalis is a different active drug from tadalafil | No — Megalis contains tadalafil |
| Every documented strength has identical manufacturer evidence | No |
| Macleods is explicitly documented as manufacturer of Megalis 10 mg and 20 mg in current regulatory records | Yes |
| Megalis and Cialis are the same finished product | No |
| Matching milligram strength proves FDA therapeutic equivalence | No |
| 5 mg, 10 mg and 20 mg are a mandatory dosing sequence | No |
Megalis is a branded tadalafil tablet family associated with Macleods Pharmaceuticals. Current Indian records document 5 mg, 10 mg and 20 mg presentations, while active regulatory records independently document Megalis 10 mg and 20 mg as tadalafil tablets manufactured by Macleods Pharmaceuticals Ltd. in India.
The evidence supports precise role wording rather than one blanket company claim. Macleods is currently identified as marketer in Indian Megalis listings, while direct manufacturer attribution is especially strong for the specific 10 mg and 20 mg regulatory products.
Megalis shares tadalafil and common nominal strengths with other tadalafil products, including Cialis, but those similarities do not establish identical finished-product identity, FDA approval or therapeutic equivalence. Those conclusions require evidence tied to the exact product and jurisdiction.
Megalis is a branded tadalafil tablet family associated with Macleods Pharmaceuticals.
The documented active ingredient in Megalis is tadalafil.
Current product records document Megalis tadalafil tablets in 5 mg, 10 mg and 20 mg strengths.
Current Indian market records identify Macleods Pharmaceuticals Pvt Ltd as marketer of documented Megalis products.
Yes for specific products. Current regulatory records explicitly identify Macleods Pharmaceuticals Ltd. in India as manufacturer of documented Megalis 10 mg and 20 mg tablets.
The current evidence used here establishes the Macleods company association for Megalis 5 mg through Indian market records, but this page does not extend the separate 10 mg and 20 mg regulatory manufacturer evidence to the 5 mg product without equivalent product-specific documentation.
Current Indian records show Megalis 5 mg in a ten-tablet strip and Megalis 10 mg and 20 mg in four-tablet presentations. Commercial packaging can change over time.
No. Both can contain tadalafil and can overlap in strength, but they are different branded finished products.
Both state 20 mg of tadalafil at the active-ingredient strength level. That fact alone does not establish regulatory or therapeutic equivalence.
The Megalis sources used for this page do not establish the Megalis-branded finished product as an FDA-approved generic of Cialis. U.S. approval and therapeutic-equivalence status must be checked for the exact product.
No. They are documented product strengths, not a mandatory dose-escalation sequence.
No. Regulatory approval is jurisdiction-specific, so a Nigerian registration does not establish FDA approval.
No. The same company can perform both roles, but each role should be supported by product-specific evidence rather than assumed.